Trinity Biotech Q2 EPADS $(0.16) Misses $(0.09) Estimate, Sales $13.90M Beat $13.50M Estimate
Portfolio Pulse from Benzinga Newsdesk
Trinity Biotech (NASDAQ:TRIB) reported Q2 losses of $(0.16) per share, missing the analyst consensus estimate of $(0.09) by 77.78%. However, the company's quarterly sales of $13.90 million beat the analyst consensus estimate of $13.50 million by 2.95%.
October 03, 2023 | 1:18 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Trinity Biotech's Q2 earnings per share missed estimates by 77.78%, but sales beat estimates by 2.95%.
Trinity Biotech's Q2 results were mixed, with earnings per share missing estimates significantly, which could negatively impact the stock. However, the company's sales beat estimates, which could offset some of the negative impact from the earnings miss.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100